FDA Issues Sales Ban on Vuse Solo Menthol E-Cigarette Products

Mar.18.2023
FDA Issues Sales Ban on Vuse Solo Menthol E-Cigarette Products
The FDA bans two Vuse Solo menthol e-cigarette products due to lack of evidence supporting their public health benefit.

On March 17th, the US Food and Drug Administration (FDA) issued a ban on the sale of two menthol-flavored e-cigarette products from the Vuse Solo brand owned by Reynolds American Inc. The ban is applicable to "Vuse Replacement Cartridge Menthol 4.8% G1" and "Vuse Replacement Cartridge Menthol 4.8% G2".


Currently, Renault is not allowed to sell these products in the United States or they will face enforcement action from the FDA. However, the company can resubmit an application to address the product defects involved in the MDO constraints.


The FDA has requested that applicants disclose whether mint-flavored e-cigarettes are more beneficial compared to tobacco-flavored e-cigarettes.


The FDA evaluates tobacco products for public health standards before they can be marketed through a Pre-Market Tobacco Application (PMTA). Upon reviewing the company's PMTA, the FDA determined that the application lacked sufficient evidence to prove that allowing the product to be sold would be in the best interest of public health, as required by the 2009 Family Smoking Prevention and Tobacco Control Act. Specifically, the evidence presented by the applicant did not demonstrate that mint-flavored e-cigarettes were less harmful to the adult smoking population compared to tobacco-flavored e-cigarettes.


Existing evidence, including data from the 2022 National Youth Tobacco Survey (NYTS), suggests that non-tobacco flavored e-cigarettes, including mint-flavored e-cigarettes, pose significant risks in terms of attraction, intake, and use among youths. In contrast, data indicates that tobacco-flavored e-cigarettes do not have the same appeal to young people and therefore do not pose the same risks. Given these existing differences in youth risks, the applicant needs to provide strong evidence to demonstrate that the use of their mint-flavored e-cigarette products can greatly reduce cigarette use among adult smokers compared to tobacco-flavored e-cigarettes.


According to data from The New York Times, Vuse is the second most popular brand among teenage e-cigarette users. The FDA aims to ensure not only that the manufacturers comply, but also that the distributors and retailers comply. Retailers who have any doubts about their inventory should contact Reynolds.


This is not the first action taken by the FDA.


This recent action is just one of many taken by the FDA to ensure that tobacco products sold in the United States undergo scientific review and receive PMTA approval. So far, the agency has received over 26 million PMTA applications and has made decisions on 99% of them. Currently, the FDA has approved 23 flavored electronic cigarettes for sale or distribution in the United States, which are the only ones allowed on the market legally.


The FDA has also rejected millions of non-compliant marketing applications, including 10 non-tobacco-flavored e-cigarette pods under the Vuse Solo brand. On January 24 of this year, the FDA also issued marketing bans (MODs) for two products by Reynolds American Inc., including the Vuse Vibe Tank Menthol 3.0% and Vuse Ciro Cartridge Menthol 1.5%.


In October 2022, the FDA issued an MDO (Modified Risk Order) for several mint-flavored e-cigarette products sold by Logic Technology Development. This was the first time the FDA had issued an MDO for products containing menthol after undergoing scientific review. However, a few days later, Logic received an order from the US Third Circuit Court of Appeals, which temporarily suspended the MDO's enforcement.


References:


The FDA has refused to allow two Vuse Solo menthol e-cigarette products to be marketed.


Related reading:


The FDA has announced that it has rendered decisions on 99% of the PMTA applications for electronic cigarettes, and intends to review the remaining popular products by the end of the year.


The FDA issues a marketing refusal order for two Vuse products.


Renault, a tobacco company owned by British American Tobacco, plans to appeal against the marketing ban imposed by the FDA.


The FDA has filed civil lawsuits and imposed fines against four electronic cigarette liquid manufacturers for the first time.


The FDA has scheduled a public hearing on April 12th to discuss the creation of new regulations for the manufacturing of tobacco products.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City's Department of Consumer and Worker Protection (DCWP) opened applications on November 2, 2026, for a lottery covering tobacco and electronic cigarette retail dealer licenses, with a deadline of 5 p.m. New York local time on November 30. According to the city's October 1 notice, 55 electronic cigarette retail license slots are available across 23 community districts, including 28 in Brooklyn, alongside 322 tobacco retail license slots across 41 districts. Businesses must enter the lottery and, if invited, complete licensing requirements within 65 days. New York City continues to restrict e-cigarette retail sales to tobacco-flavored or unflavored products, while city retail licenses do not replace FDA product marketing authorization.
Market
Nov.04
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin's electronic vaping device directory has been fully enforced for more than a year, and local vape retailers say the reduced range of eligible products has contributed to declining sales, store closures and layoffs. Johnny Vapes owner Ben Hall said he has closed four of seven locations and cut about 70% of his staff. State law bars the sale of vaping devices not listed on the Wisconsin Department of Revenue directory and allows penalties of $1,000 per day for each unlisted device sold or offered for sale. In April 2026, the U.S. Court of Appeals for the Seventh Circuit allowed enforcement of the law to continue.
Regulations
Oct.10
South Korea's Synthetic Nicotine Tax Take Estimated at Just 1.3% of Forecast as Imports Plunge Nearly 97%
South Korea's Synthetic Nicotine Tax Take Estimated at Just 1.3% of Forecast as Imports Plunge Nearly 97%
After synthetic nicotine was placed under tobacco regulation on April 24, 2026, South Korea’s tax collections from synthetic-nicotine vaping products fell far short of government projections. The Chosun Ilbo reported on November 18 that Ministry of Health and Welfare data showed national health promotion charges on synthetic-nicotine liquid e-cigarettes totaled 765 million won from April 24 through September. Using statutory rates, the newspaper estimated combined major taxes and charges at about 2.622 billion won—on a monthly basis roughly 1.3% of an earlier forecast after temporary tax reductions. Customs data showed synthetic-nicotine imports dropped from about 1,467 metric tons in January–April to 45 metric tons in May–August, a nearly 97% decline. Imports of nicotine-analog and nicotine-free liquids totaled 151 metric tons in May–August, exceeding synthetic-nicotine imports in the same period, though both categories were also below January–April volumes.
Regulations
Nov.19